ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 273-275

  Ceconi, Claudio ^a   Fox, Kim M ^b   Remme, William J ^c   Simoons, Maarten L ^d   Deckers, Jaap W ^d   Bertrand, Michel ^e   Parrinello, Giovanni ^f   Kluft, Cornelius ^g   Blann, Andrew ^h   Cokkinos, Dennis ⁱ   Ferrari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Cardiovascular Research Foundation   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Medical Statistics Unit   (Italy)

^g TNO   (Netherlands)

^h UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

ⁱ ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

ACE inhibition; Coronary artery disease; Inflammation; Perindopril; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; PERINDOPRIL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 67349207802     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.042     Document Type: Article

References (11)

1. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
2. PERTINENT-perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17:83-91.
3. Ceconi C., Fox K.M., Remme W.J., et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 73 (2007) 237-246
4. de Maat M.P., de Bart A.C., Hennis B.C., et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 16 (1996) 1156-1162
5. von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17 (1957) 237-246
6. Jager A., van Hinsbergh V.W., Kostense P.J., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19 (1999) 3071-3078
7. Tataru M.C., Heinrich J., Junker R., et al. d-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 20 (1999) 1493-1502
8. Smith A., Patterson C., Yarnell J., Rumley A., Ben Shlomo Y., and Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112 (2005) 3080-3087
9. Jialal I., Devaraj S., and Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 44 (2004) 6-11
10. Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol 98 (2005) 199-206
11. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention evaluation study investigators. N Engl J Med 342 (2000) 145-153